Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.05.28.446009Source: DataRank Database

Combination of a Sindbis-SARS-CoV-2 spike vaccine and αOX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2021). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)OA: greenTopics (47)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Silvana Opp ORCID,Alicia Hurtado ORCID,Ziyan Lin ORCID,Christine Pampeno ORCID,María G. Noval ORCID

Live enrichment

PubMed:34075383 OpenAlex:https://openalex.org/W3165280030

National Institutes of Health

Grant: 5R44CA206606-02

A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy

NCI NIH HHS

Grant: R44 CA206606

NCI NIH HHS

Grant: R44 CA250627

greenLicense: cc-by-nc-nd

repositoryhttps://www.biorxiv.org/content/biorxiv/early/2021/06/02/2021.05.28.446009.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2021.05.28.446009

repositoryhttps://doi.org/10.1101/2021.05.28.446009

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34075383

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studiesvaccines and immunoinformatics approaches0301 basic medicine03 medical and health sciences

Keywords

BiologyVirologyImmune systemAntibodyImmunologySindbis virusAlphavirusPopulationImmunityAcquired immune systemVirusMedicineGeneGeneticsalphavirus vaccinesynergistic combination SARS-CoV-2 vaccine strategyCOVID-19 VaccinesCOVID19T-LymphocytesMice, TransgenicAntibodies, ViralArticleMiceCricetinaeAnimalsHumansSindbis virus vaccineSARS-CoV-2SARS-CoV-2 immunityVaccinationCOVID-19RC581-607Antibodies, NeutralizingAntigens, DifferentiationMice, Inbred C57BLHEK293 CellsαOX40Spike Glycoprotein, CoronavirusFemaleAngiotensin-Converting Enzyme 2Immunologic diseases. AllergySARS-CoV-2 vaccine

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being